Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis

Aguilo, Nacho (Universidad de Zaragoza) ; Gonzalo-Asensio, Jesús (Universidad de Zaragoza) ; Alvarez-Arguedas, Samuel (Universidad de Zaragoza) ; Marinova, Dessislava (Universidad de Zaragoza) ; Gomez, Ana Belen (Universidad de Zaragoza) ; Uranga, Santiago (Universidad de Zaragoza) ; Spallek, Ralf ; Singh, Mahavir ; Audran, Regine ; Spertini, François ; Martin, Carlos (Universidad de Zaragoza)
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis
Financiación H2020 / H2020 Funds
Resumen: MTBVAC is a live-attenuated Mycobacterium tuberculosis vaccine, currently under clinical development, that contains the major antigens ESAT6 and CFP10. These antigens are absent from the current tuberculosis vaccine, BCG. Here we compare the protection induced by BCG and MTBVAC in several mouse strains that naturally express different MHC haplotypes differentially recognizing ESAT6 and CFP10. MTBVAC induces improved protection in C3H mice, the only of the three tested strains reactive to both ESAT6 and CFP10. Deletion of both antigens in MTBVAC reduces its efficacy to BCG levels, supporting a link between greater efficacy and CFP10- and ESAT6-specific reactogenicity. In addition, MTBVAC (but not BCG) triggers a specific response in human vaccinees against ESAT6 and CFP10. Our results warrant further exploration of this response as potential biomarker of protection in MTBVAC clinical trials.
Idioma: Inglés
DOI: 10.1038/ncomms16085
Año: 2017
Publicado en: Nature Communications 8 (2017), 16085 [11 pp.]
ISSN: 2041-1723

Factor impacto JCR: 12.353 (2017)
Categ. JCR: MULTIDISCIPLINARY SCIENCES rank: 3 / 64 = 0.047 (2017) - Q1 - T1
Factor impacto SCIMAGO: 6.582 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1) - Physics and Astronomy (miscellaneous) (Q1) - Chemistry (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
Financiación: info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P
Tipo y forma: Article (Published version)
Área (Departamento): Área Microbiología (Dpto. Microb.Med.Pr.,Sal.Públ.)
Área (Departamento): Proy. investigación HQA (Dpto. Microb.Med.Pr.,Sal.Públ.)


Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.


Exportado de SIDERAL (2021-05-26-09:31:16)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Articles



 Record created 2017-08-30, last modified 2021-05-26


Versión publicada:
 PDF
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)